Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects
To assess the impact of sugammadex on activated partial thromboplastin time (APTT) and international normalized ratio for prothrombin time (PT(INR)) in healthy subjects and characterize the concentration-dependency of sugammadex effects on APTT and prothrombin time (PT) in normal human plasma in vit...
Saved in:
| Published in: | International journal of clinical pharmacology and therapeutics Vol. 52; no. 3; p. 227 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Germany
01.03.2014
|
| Subjects: | |
| ISSN: | 0946-1965 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | To assess the impact of sugammadex on activated partial thromboplastin time (APTT) and international normalized ratio for prothrombin time (PT(INR)) in healthy subjects and characterize the concentration-dependency of sugammadex effects on APTT and prothrombin time (PT) in normal human plasma in vitro.
Eight healthy subjects (18 - 45 years of age) were administered intravenous doses of 4 mg/kg sugammadex, 16 mg/kg sugammadex, or placebo in a randomized, placebo-controlled, three period cross-over trial. The primary endpoint was area under the curve from 2 to 60 minutes post-dose (AUC2-60min) for APTT and PT(INR). In vitro, the effects of sugammadex on APTT and PT were assessed in pooled normal human citrate plasma.
In subjects dosed with 4 and 16 mg/kg sugammadex, geometric mean ratios (treated vs. placebo) for AUC2-60min were 1.085 (95% confidence interval, 0.888 - 1.325) and 1.019 (0.868 - 1.195), respectively, for APTT, and 1.047 (0.904 - 1.213) and 1.096 (0.953 - 1.261), respectively, for PT(INR). At individual timepoints, mean APTT and PT(INR) increased by up to 22% after 16 mg/kg sugammadex compared with placebo. All such increases occurred within 30 minutes post-dose. Sugammadex was generally well tolerated. In the in vitro experiments, addition of sugammadex to plasma resulted in limited, concentration dependent increases in both APTT and PT. At 200 μg/mL (the mean maximum concentration reached therapeutically), the relative increases were 29% and 19%, respectively.
Administration of sugammadex is associated with a dose-related, limited and transient prolongation of APTT and PT(INR) that is unlikely to be of clinical relevance. |
|---|---|
| AbstractList | To assess the impact of sugammadex on activated partial thromboplastin time (APTT) and international normalized ratio for prothrombin time (PT(INR)) in healthy subjects and characterize the concentration-dependency of sugammadex effects on APTT and prothrombin time (PT) in normal human plasma in vitro.
Eight healthy subjects (18 - 45 years of age) were administered intravenous doses of 4 mg/kg sugammadex, 16 mg/kg sugammadex, or placebo in a randomized, placebo-controlled, three period cross-over trial. The primary endpoint was area under the curve from 2 to 60 minutes post-dose (AUC2-60min) for APTT and PT(INR). In vitro, the effects of sugammadex on APTT and PT were assessed in pooled normal human citrate plasma.
In subjects dosed with 4 and 16 mg/kg sugammadex, geometric mean ratios (treated vs. placebo) for AUC2-60min were 1.085 (95% confidence interval, 0.888 - 1.325) and 1.019 (0.868 - 1.195), respectively, for APTT, and 1.047 (0.904 - 1.213) and 1.096 (0.953 - 1.261), respectively, for PT(INR). At individual timepoints, mean APTT and PT(INR) increased by up to 22% after 16 mg/kg sugammadex compared with placebo. All such increases occurred within 30 minutes post-dose. Sugammadex was generally well tolerated. In the in vitro experiments, addition of sugammadex to plasma resulted in limited, concentration dependent increases in both APTT and PT. At 200 μg/mL (the mean maximum concentration reached therapeutically), the relative increases were 29% and 19%, respectively.
Administration of sugammadex is associated with a dose-related, limited and transient prolongation of APTT and PT(INR) that is unlikely to be of clinical relevance. To assess the impact of sugammadex on activated partial thromboplastin time (APTT) and international normalized ratio for prothrombin time (PT(INR)) in healthy subjects and characterize the concentration-dependency of sugammadex effects on APTT and prothrombin time (PT) in normal human plasma in vitro.OBJECTIVESTo assess the impact of sugammadex on activated partial thromboplastin time (APTT) and international normalized ratio for prothrombin time (PT(INR)) in healthy subjects and characterize the concentration-dependency of sugammadex effects on APTT and prothrombin time (PT) in normal human plasma in vitro.Eight healthy subjects (18 - 45 years of age) were administered intravenous doses of 4 mg/kg sugammadex, 16 mg/kg sugammadex, or placebo in a randomized, placebo-controlled, three period cross-over trial. The primary endpoint was area under the curve from 2 to 60 minutes post-dose (AUC2-60min) for APTT and PT(INR). In vitro, the effects of sugammadex on APTT and PT were assessed in pooled normal human citrate plasma.METHODSEight healthy subjects (18 - 45 years of age) were administered intravenous doses of 4 mg/kg sugammadex, 16 mg/kg sugammadex, or placebo in a randomized, placebo-controlled, three period cross-over trial. The primary endpoint was area under the curve from 2 to 60 minutes post-dose (AUC2-60min) for APTT and PT(INR). In vitro, the effects of sugammadex on APTT and PT were assessed in pooled normal human citrate plasma.In subjects dosed with 4 and 16 mg/kg sugammadex, geometric mean ratios (treated vs. placebo) for AUC2-60min were 1.085 (95% confidence interval, 0.888 - 1.325) and 1.019 (0.868 - 1.195), respectively, for APTT, and 1.047 (0.904 - 1.213) and 1.096 (0.953 - 1.261), respectively, for PT(INR). At individual timepoints, mean APTT and PT(INR) increased by up to 22% after 16 mg/kg sugammadex compared with placebo. All such increases occurred within 30 minutes post-dose. Sugammadex was generally well tolerated. In the in vitro experiments, addition of sugammadex to plasma resulted in limited, concentration dependent increases in both APTT and PT. At 200 μg/mL (the mean maximum concentration reached therapeutically), the relative increases were 29% and 19%, respectively.RESULTSIn subjects dosed with 4 and 16 mg/kg sugammadex, geometric mean ratios (treated vs. placebo) for AUC2-60min were 1.085 (95% confidence interval, 0.888 - 1.325) and 1.019 (0.868 - 1.195), respectively, for APTT, and 1.047 (0.904 - 1.213) and 1.096 (0.953 - 1.261), respectively, for PT(INR). At individual timepoints, mean APTT and PT(INR) increased by up to 22% after 16 mg/kg sugammadex compared with placebo. All such increases occurred within 30 minutes post-dose. Sugammadex was generally well tolerated. In the in vitro experiments, addition of sugammadex to plasma resulted in limited, concentration dependent increases in both APTT and PT. At 200 μg/mL (the mean maximum concentration reached therapeutically), the relative increases were 29% and 19%, respectively.Administration of sugammadex is associated with a dose-related, limited and transient prolongation of APTT and PT(INR) that is unlikely to be of clinical relevance.CONCLUSIONSAdministration of sugammadex is associated with a dose-related, limited and transient prolongation of APTT and PT(INR) that is unlikely to be of clinical relevance. |
| Author | Langdon, Ronald B Grobara, Peter De Kam, Pieter-Jan Kluft, Cornelis Höppener, Floris Peeters, Pierre Burggraaf, Jacobus Prohn, Marita |
| Author_xml | – sequence: 1 givenname: Pieter-Jan surname: De Kam fullname: De Kam, Pieter-Jan – sequence: 2 givenname: Peter surname: Grobara fullname: Grobara, Peter – sequence: 3 givenname: Marita surname: Prohn fullname: Prohn, Marita – sequence: 4 givenname: Floris surname: Höppener fullname: Höppener, Floris – sequence: 5 givenname: Cornelis surname: Kluft fullname: Kluft, Cornelis – sequence: 6 givenname: Jacobus surname: Burggraaf fullname: Burggraaf, Jacobus – sequence: 7 givenname: Ronald B surname: Langdon fullname: Langdon, Ronald B – sequence: 8 givenname: Pierre surname: Peeters fullname: Peeters, Pierre |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24447651$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kMtOwzAQRb0oog-Q-ALkJZuA30mWqCoFqRIsuo8mjt2miuMSO4j-PUZtV1eac-doNHM06X1vEHqg5FkKKl6WX4zQMlcTNCOlUBktlZyieQgHQpiUeXmLpkwIkStJZ2i3stboGLC3OIw7cA4a84t9j0HH9geiafARhthCh-N-8K72xw5CbHscW2cw9IkP_oyuw5R7A13cn5KzPvz779CNhS6Y-0su0PZttV2-Z5vP9cfydZNpTnnMbKEKJWqhCgGNlUXZlEA0NzZXDRdADSsTYporpSVNVOQFl1TKQljFNVugp7M23fQ9mhAr1wZtug5648dQUUloWsiFStXHS3WsnWmq49A6GE7V9TfsDwQtZUs |
| CitedBy_id | crossref_primary_10_1177_0310057X1504300104 crossref_primary_10_1517_14656566_2016_1145667 crossref_primary_10_1007_s40265_016_0604_1 crossref_primary_10_3390_medicina61030378 crossref_primary_10_1097_ALN_0000000000000868 crossref_primary_10_1016_j_jclinane_2017_03_004 crossref_primary_10_1177_08971900211048747 crossref_primary_10_2147_DDDT_S286803 crossref_primary_10_1007_s40140_018_0266_5 crossref_primary_10_1016_j_bjane_2020_10_004 crossref_primary_10_1097_MD_0000000000010129 crossref_primary_10_3390_jcm12113633 crossref_primary_10_1186_s12871_020_00986_z crossref_primary_10_1097_ALN_0000000000001076 crossref_primary_10_1038_s41598_020_68164_2 crossref_primary_10_1016_j_bjan_2020_08_007 crossref_primary_10_7759_cureus_14521 crossref_primary_10_1097_PEC_0000000000002126 crossref_primary_10_1097_ALN_0000000000000424 crossref_primary_10_1177_08971900231185817 crossref_primary_10_2147_DDDT_S328682 crossref_primary_10_1080_14656566_2017_1280461 crossref_primary_10_1016_j_jclinane_2017_06_006 crossref_primary_10_1016_j_jemermed_2020_08_006 crossref_primary_10_1080_14740338_2019_1649393 crossref_primary_10_1186_s12871_018_0519_3 crossref_primary_10_1016_j_ejps_2015_12_028 crossref_primary_10_1213_ANE_0000000000006275 crossref_primary_10_1186_s12871_025_03041_x crossref_primary_10_1155_2015_708915 crossref_primary_10_1186_s12871_017_0429_9 crossref_primary_10_3390_diagnostics15070941 crossref_primary_10_1093_bja_aev448 crossref_primary_10_3390_jcm11236951 crossref_primary_10_1097_ALN_0000000000000853 crossref_primary_10_2174_1381612825666190704101145 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.5414/CP201976 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| ExternalDocumentID | 24447651 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .GJ 36B 3V. 53G 5GY 7X7 88E 8FI 8FJ ABJNI ABUWG ACGFO ACGFS ADBBV AENEX AFFNX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR BPHCQ BVXVI CCPQU CGR CUY CVF DLWAR EBS ECM EIF EJD EMB EMOBN F5P FYUFA HMCUK M1P MK0 NPM P2P PQQKQ PROAC PSQYO SJN SV3 UKHRP VDS ZGI ZXP ~4P 7X8 |
| ID | FETCH-LOGICAL-c313t-f86864b4684adf589d9a0c3ef76d34a1e296842c366c519d94783515584f63c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 44 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000333511000006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0946-1965 |
| IngestDate | Thu Sep 04 18:37:39 EDT 2025 Thu Jan 02 22:15:43 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c313t-f86864b4684adf589d9a0c3ef76d34a1e296842c366c519d94783515584f63c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 24447651 |
| PQID | 1501835746 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1501835746 pubmed_primary_24447651 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-03-01 |
| PublicationDateYYYYMMDD | 2014-03-01 |
| PublicationDate_xml | – month: 03 year: 2014 text: 2014-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany |
| PublicationTitle | International journal of clinical pharmacology and therapeutics |
| PublicationTitleAlternate | Int J Clin Pharmacol Ther |
| PublicationYear | 2014 |
| References | 24986096 - Int J Clin Pharmacol Ther. 2014 Sep;52(9):824 |
| References_xml | – reference: 24986096 - Int J Clin Pharmacol Ther. 2014 Sep;52(9):824 |
| SSID | ssj0025579 |
| Score | 2.2448468 |
| Snippet | To assess the impact of sugammadex on activated partial thromboplastin time (APTT) and international normalized ratio for prothrombin time (PT(INR)) in healthy... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 227 |
| SubjectTerms | Adult Cross-Over Studies Dose-Response Relationship, Drug Female gamma-Cyclodextrins - adverse effects gamma-Cyclodextrins - pharmacokinetics gamma-Cyclodextrins - pharmacology Humans International Normalized Ratio Male Partial Thromboplastin Time Prothrombin Time Young Adult |
| Title | Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24447651 https://www.proquest.com/docview/1501835746 |
| Volume | 52 |
| WOSCitedRecordID | wos000333511000006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV27TsMwFLWAMrDwfpSXjIQ61aJNHMeZEKqoGKDK0KFb5GfVoUlo2or-Pdd1SickJJZEipWH7BP76F7fcxB61NTqjg4kCbjhhEoZE6kSTiJjutoAhrhc68y-x4MBH42StA64VfW2ys2cuJ6odaFcjPyp65Tnwiim7Ln8JM41ymVXawuNXdQIgco4VMejnywCsOVaa48y4pTzvPisM75-6qWw8iUx-51YrheY_tF_P-0YHdbUEr94LJygHZOfolbqtalXbTzcllpVbdzC6Va1enWGxl7HuMKFxdViLKZToc0XLnLsSh-WQEk1Lh3O4BXOW2EqixKY93ySY-dPj0UO7bPCN20uwtkXWq7gmdKFfKpzNOy_DntvpHZhIAr6dE4sZ5xRSRmnQtuIJzoRHRUaGzMdUtE1QeJyeSpkTAEd1Al1wSSgKZxaFqrgAu3lRW6uELZAriItWSBURKnsCCeMAwyJC0kNs1ETPWz6NwOQu8yFyE2xqLJtDzfRpR-krPRqHBnwExqzqHv9h7tv0AEMO_V7yG5Rw8Ivbu7QvlrOJ9Xsfo0eOA7Sj29wQdGR |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+sugammadex+on+activated+partial+thromboplastin+time+and+prothrombin+time+in+healthy+subjects&rft.jtitle=International+journal+of+clinical+pharmacology+and+therapeutics&rft.au=De+Kam%2C+Pieter-Jan&rft.au=Grobara%2C+Peter&rft.au=Prohn%2C+Marita&rft.au=H%C3%B6ppener%2C+Floris&rft.date=2014-03-01&rft.issn=0946-1965&rft.volume=52&rft.issue=3&rft.spage=227&rft_id=info:doi/10.5414%2FCP201976&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0946-1965&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0946-1965&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0946-1965&client=summon |